{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:30:04Z","timestamp":1789695004920,"version":"4.0.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.09.016","type":"journal-article","created":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T09:08:56Z","timestamp":1540717736000},"page":"247-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Hypothalamitis and severe hypothalamic dysfunction associated with anti\u2013programmed cell death ligand 1 antibody treatment"],"prefix":"10.1016","volume":"104","author":[{"given":"N.","family":"Tshuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-8191","authenticated-orcid":false,"given":"N.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Evanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.09.016_bib1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2217\/imt.15.91","article-title":"Checkpoint inhibitors in bladder and renal cancers: results and perspectives","volume":"7","author":"Aoun","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejca.2018.09.016_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ejca.2018.09.016_bib3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"27","author":"Naidoo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.016_bib4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.016_bib5","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1016\/j.clgc.2017.03.001","article-title":"Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature","volume":"15","author":"Levine","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2018.09.016_bib6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejca.2018.09.016_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.09.016_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.09.016_bib9","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T08:24:03Z","timestamp":1549009443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":9,"alternative-id":["S0959804918313868"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypothalamitis and severe hypothalamic dysfunction associated with anti\u2013programmed cell death ligand 1 antibody treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}